Your browser doesn't support javascript.
loading
Determination of optimal vibration dose to treat Parkinson's disease gait symptoms: A clinical trial.
Pretzer-Aboff, Ingrid; Elswick, R K; Gouelle, Arnaud; Helm, Noah; Blackwell, GinaMari; Cloud, Leslie.
Afiliação
  • Pretzer-Aboff I; Virginia Commonwealth University, School of Nursing, 1100 East Leigh St., Office 3063, Richmond, VA 23298, United States.
  • Elswick RK; Virginia Commonwealth University, School of Nursing, 1100 East Leigh St., Office 3063, Richmond, VA 23298, United States.
  • Gouelle A; Université Reims Champagne Ardenne, UFR STAPS, Laboratory "Performance Santé Métrologie Société", Reims, France.
  • Helm N; Virginia Commonwealth University Health System, Comprehensive Medicine Unit, Richmond, VA 23298, United States.
  • Blackwell G; Virginia Commonwealth University School of Medicine, Department of Neurology, Parkinson's & Movement Disorders Center, Richmond, VA 23298, United States.
  • Cloud L; Virginia Commonwealth University School of Medicine, Department of Neurology, Parkinson's & Movement Disorders Center, Richmond, VA 23298, United States.
Clin Park Relat Disord ; 10: 100248, 2024.
Article em En | MEDLINE | ID: mdl-38549683
ABSTRACT

Introduction:

Most people with Parkinson's disease (PD) will experience gait problems. Previous studies demonstrated improved gait and balance after vibration stimulation was applied to the feet of PD patients. However, not all study participants showed improvement, perhaps due to sub-optimal vibration stimulus. Thus far, the optimal frequency and amplitude of vibration for mitigating gait dysfunction in PD have yet to be systematically explored. This study aimed to deliver vibration to the feet of 26 people with PD gait disturbances. We hypothesized that a global frequency, amplitude, and minimum duration of vibration therapy are required to improve PD gait issues.

Methods:

This was a phase Ib trial to identify optimal vibration parameters. Thirteen participants were recruited at Hoehn & Yahr (H&Y) stage II and 13 participants at stage III. Each group was randomly assigned to different frequency and amplitude settings prescribed by the central composite design methodology. Each participant received vibration for 18 min per walking session, for eight sessions spread over one week.

Results:

Results showed an optimal response to treatment for frequency (Hz) and amplitude (mm) of vibration based on the Functional Ambulation Performance score for stages II and III. In the H&Y stage II group, stabilization of outcomes occurred after the 4th treatment. This stabilization was not seen in stage III participants.

Conclusions:

A global frequency and vibration amplitude have been identified for treating PD gait disorders. Patients with more advanced disease may require a longer duration of therapy.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Park Relat Disord Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Clin Park Relat Disord Ano de publicação: 2024 Tipo de documento: Article